FA2H is a human gene. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration. [@wang2017]
FA2H (Fatty Acid 2-Hydroxylase) encodes a transmembrane enzyme localized to the endoplasmic reticulum that catalyzes the 2-hydroxylation of fatty acids, producing 2-hydroxy fatty acids (2-OH FAs) that are essential components of myelin lipids. The FA2H enzyme plays a critical role in lipid metabolism, particularly in the synthesis of 2-hydroxy galactosylceramide and 2-hydroxy glucosylceramide, which are enriched in the myelin sheath. Pathogenic variants in FA2H cause hereditary spastic paraplegia (HSP) type 35 (SPG35) and have been implicated in neurodegeneration through disruptions of lipid metabolism, oxidative stress, and neuroinflammation. The gene is located on chromosome 16q23.1 and consists of 13 exons. [@keller2019]
¶ Gene Structure and Protein Function
FA2H is a member of the fatty acid hydroxylase family characterized by: [@snaidero2020]
- Topology: Multiple transmembrane domains spanning the ER membrane
- Active site: Cytoplasmic-facing catalytic domain containing the diiron center
- Cofactor requirement: Iron and oxygen for hydroxylation reaction
- Substrate specificity: Preferential activity toward C16-C24 fatty acyl-CoA substrates
The 2-hydroxylation reaction proceeds through: [@nave2014]
- Substrate (fatty acyl-CoA) binding to the active site
- Oxygen binding to the diiron center
- Hydrogen abstraction from the C2 position
- Hydroxyl radical addition to generate 2-hydroxy fatty acid
- Product release and CoA recycling
FA2H produces 2-hydroxy fatty acids that are incorporated into: [@simons2013]
| Lipid Type | Structure | Tissue Distribution | [@chrast2011]
|------------|-----------|---------------------| [@macklin2018]
| 2-OH galactosylceramide | Galactose-2-OH FA-ceramide | CNS myelin | [@morell2019]
| 2-OH glucosylceramide | Glucose-2-OH FA-ceramide | Skin epidermis | [@baumann2001]
| 2-OH sulfatide | Sulfate-2-OH FA-ceramide | Myelin internodes | [@zhang2020]
| 2-OH ceramide | Base-2-OH FA | Universal | [@fancy2009]
The myelin sheath contains exceptionally high concentrations of 2-hydroxy fatty acids: [@kutz2015]
- 2-hydroxygalactosylceramide comprises ~30% of myelin galactolipids
- These lipids stabilize myelin structure through hydrogen bonding
- 2-OH groups enhance lipid packing and membrane cohesion
- Loss of 2-hydroxylation disrupts myelin ultrastructure
FA2H is highly expressed in oligodendrocyte precursor cells (OPCs) and maturing oligodendrocytes: [@bergles2015]
- Required for proper myelin sheath formation during development
- Maintains myelin lipid composition in adult CNS
- Supports myelin repair following demyelination
- Dysregulation leads to hypomyelination
Beyond myelin formation, FA2H supports axonal health through: [@trapp2018]
- Regulation of lipid raft composition
- Modulation of neurotrophin signaling
- Protection against oxidative stress
- Maintenance of axonal transport
Biallelic pathogenic variants in FA2H cause autosomal recessive SPG35: [@bradl2010]
- Progressive lower limb spasticity and weakness
- Cognitive impairment in ~40% of cases
- Peripheral neuropathy in some patients
- Onset typically in childhood or adolescence
- Variable progression rate
- Thin corpus callosum
- White matter abnormalities on MRI
- Cerebral atrophy in severe cases
- Cerebellar involvement in some variants
| Variant Type | Effect | Phenotype | [@miron2011]
|--------------|--------|-----------| [@kotter2006]
| Missense | Partial enzyme loss | Mild HSP | [@franklin2008]
| Nonsense | Truncated protein | Severe HSP + cognitive | [@patani2013]
| Frameshift | No functional protein | Early-onset severe | [@wang2016]
| Splice site | Exon skipping | Variable |
Emerging evidence links FA2H to Parkinson's disease:
- Rare missense variants identified in PD patients
- Expression changes in PD substantia nigra
- Meta-analysis suggests modest risk contribution
- Possible interaction with alpha-synuclein metabolism
- Lipid dysregulation affects alpha-synuclein aggregation
- Impaired myelin maintenance in PD substantia nigra
- Altered fatty acid metabolism in dopamine neurons
- Inflammation-related pathway disruption
- Multiple sclerosis: Altered FA2H expression in lesions
- Metachromatic leukodystrophy: Potential modifier gene
- Alexander disease: Possible lipid metabolism involvement
- Amyotrophic lateral sclerosis: Rare variant associations
FA2H deficiency leads to neurodegeneration through:
- Reduced 2-hydroxy galactolipid content
- Structural myelin abnormalities
- Impaired conduction velocity
- Secondary axonal degeneration
- Altered membrane microdomain composition
- Disrupted signaling platform function
- Impaired neurotrophin receptor trafficking
- Altered ion channel localization
- Accumulation of unmetabolized substrates
- Unfolded protein response activation
- Calcium homeostasis disruption
- Pro-apoptotic signaling
Pathogenic variants disrupt lipid homeostasis:
- Accumulation of non-hydroxy fatty acids
- Reduced sulfatide content
- Impaired cholesterol trafficking
- Altered ganglioside composition
FA2H deficiency triggers inflammatory responses:
- Microglial activation in white matter
- Cytokine release (IL-1β, TNF-α)
- Complement system activation
- Autoimmune-like demyelination
¶ Diagnosis and Testing
Molecular diagnosis involves:
| Method |
Application |
Detection Rate |
| Panel testing |
Known HSP genes |
~40% |
| Whole exome sequencing |
Novel variant discovery |
~60% |
| Whole genome sequencing |
Regulatory variants |
Higher |
| Segregation analysis |
Family studies |
Confirms inheritance |
- Elevated CSF sulfatide in FA2H deficiency
- Abnormal very-long-chain fatty acid profile
- Reduced 2-hydroxy fatty acids in serum
- Neurofilament light chain elevation
Diagnostic imaging findings:
- MRI: White matter hyperintensities, thin corpus callosum
- MRS: Reduced N-acetylaspartate in affected regions
- DTI: Reduced fractional anisotropy in white matter tracts
Current pharmacological strategies:
- Lactoferrin: Promotes oligodendrocyte differentiation
- Clemastine: Promotes remyelination via M1R antagonism
- Benznidazole: Potential for enhancing 2-hydroxylation
- Antioxidants: Counteract oxidative stress
Emerging therapeutic modalities:
- AAV-mediated FA2H delivery to CNS
- Lentiviral vector-based gene correction
- CRISPR-Cas9 for precise variant editing
- mRNA delivery for protein replacement
Dietary approaches under investigation:
- 2-Hydroxy fatty acid supplementation
- Galactolipid-enriched diets
- Omega-3 fatty acid co-therapy
- Lipid raft stabilizers
- OPC transplantation strategies
- Induced pluripotent stem cell (iPSC) models
- Small molecule screening for enhancers
| Model |
Species |
Key Features |
| Fa2h knockout |
Mouse |
Hypomyelination, tremor, ataxia |
| Conditional KO |
Mouse |
Oligodendrocyte-specific deletion |
| Knock-in |
Mouse |
Patient-derived variants |
| Transgenic |
Zebrafish |
Visual phenotyping |
- Primary oligodendrocyte cultures
- iPSC-derived neurons and glia
- HEK293 overexpression systems
- Patient fibroblast lines
FA2H interacts with key proteins:
- CYP4F2: Parallel fatty acid hydroxylation
- GALC: Galactolipid metabolism
- NG2: Proteoglycan in OPCs
- PLP1: Myelin protein integration
- MBP: Myelin basic protein
FA2H influences multiple pathways:
- PI3K/Akt/mTOR signaling
- MAPK/ERK pathways
- JAK/STAT signaling
- PPARγ-mediated transcription
- LXR/RXR lipid sensing
Modifying genes in FA2H-related disease:
- GALC: Substrate accumulation
- ARSA: Sulfatide metabolism
- SLC33A1: Acetyl-CoA transport
- ELOVL1: Very-long-chain FA synthesis
- SPG35: ~1-2% of recessive HSP cases
- FA2H in PD: Rare variants, unclear contribution
- Compound heterozygotes more common than homozygotes
- Founder mutations in specific populations
- Higher prevalence in populations with founder effects
- Reported cases across Europe, Asia, Middle East
- Consanguinity increases incidence
- Variable phenotype expressivity
The FA2H gene encodes a critical enzyme for myelin lipid metabolism, producing 2-hydroxy fatty acids essential for proper myelin structure and function. Pathogenic variants cause hereditary spastic paraplegia type 35 (SPG35), characterized by progressive lower limb spasticity, cognitive impairment, and white matter abnormalities. The enzyme's role in lipid metabolism and myelin maintenance has also implicated FA2H in Parkinson's disease, multiple sclerosis, and other neurodegenerative conditions. Understanding FA2H function provides insights into myelin biology, lipid homeostasis, and potential therapeutic approaches for disorders of myelin maintenance and neurodegeneration.
Recent proteomic analyses of FA2H-deficient models reveal:
| Protein |
Change |
Functional Implication |
| MBP |
Reduced |
Impaired myelin compaction |
| PLP1 |
Normal |
Structural protein preserved |
| CNP |
Increased |
Compensatory mechanism |
| MAG |
Reduced |
Axonal support compromised |
| Oligodendrocyte markers |
Variable |
Differentiation affected |
Metabolomic profiling shows:
- Accumulation of non-hydroxy fatty acids
- Reduced 2-hydroxy galactosylceramide
- Elevated very-long-chain fatty acids
- Altered phospholipid composition
- Changes in cholesterol metabolites
FA2H expression is regulated by:
- Promoter methylation: Tissue-specific expression
- Histone modifications: Active marks in oligodendrocytes
- Transcription factors: Olig2, Sox10, Nfat
- mRNA stability: AU-rich elements in 3'UTR
FA2H-related disorders must be differentiated from other causes of spasticity and white matter disease:
| Condition |
Distinguishing Features |
Key Tests |
| SPG4 (SPAST) |
Pure spasticity, no cognitive |
Genetic testing |
| SPG15 (ZFYVE19) |
Thin corpus callosum, cognitive |
MRI, genetic |
| Metachromatic leukodystrophy |
ARSA mutations |
Enzyme activity |
| Krabbe disease |
GALC deficiency |
Enzyme activity |
| Adrenoleukodystrophy |
VLCFA elevation |
Blood VLCFA |
The clinical course of FA2H-related HSP follows predictable stages:
| Stage |
Age |
Features |
| Pre-symptomatic |
Birth-5 years |
Normal exam |
| Early |
5-15 years |
Gait disturbance |
| Intermediate |
15-30 years |
Progressive spasticity |
| Late |
30+ years |
Contractures, disability |
- Contractures: Joint immobilization
- Scoliosis: Spinal deformity
- UTI: Recurrent infections
- Respiratory: Reduced mobility complications
- Cognitive: Variable decline
| Specialty |
Role |
| Neurology |
Primary care, medication |
| Orthopedics |
Contracture management |
| Physical therapy |
Mobility, function |
| Occupational therapy |
ADL optimization |
| Psychology |
Cognitive support |
| Urology |
Bladder management |
- Mobility aids: Canes, walkers, wheelchairs
- Orthotics: Ankle-foot braces
- Communication: Adaptive devices as needed
- Home modifications: Ramps, bars
- Generally normal with modern care
- Reduced in severe cases with complications
- Quality of life depends on mobility and cognition
| Factor |
Prognostic Value |
| Age at onset |
Earlier = more severe |
| Cognitive involvement |
Worsens prognosis |
| Ambulation status |
Preserved = better |
| Comorbidities |
Additional burden |
FA2H gene organization:
- Location: 16q23.1
- Genomic size: ~13 kb
- Exons: 13
- Transcript: NM_024072.4
- Protein: NP_077045.2 (383 aa)
| Variant Type |
Mechanism |
Frequency |
| Missense |
Partial loss |
Most common |
| Nonsense |
Truncated protein |
~20% |
| Frameshift |
No protein |
~15% |
| Splice site |
Exon skipping |
~15% |
| Deletion |
No protein |
Rare |
| Variant |
Effect |
Pathogenicity |
| p.Gln214* |
Nonsense |
Pathogenic |
| p.Arg270Cys |
Missense |
Likely pathogenic |
| p.Tyr365Asn |
Missense |
Likely pathogenic |
| c.634+1G>A |
Splicing |
Pathogenic |
| Domain |
Variants |
Phenotype |
| Transmembrane |
Common |
Variable |
| Catalytic domain |
Severe |
Early onset |
| C-terminal |
Mild |
Later onset |
FA2H deficiency leads to oligodendrocyte apoptosis:
- Lipid accumulation triggers ER stress
- Unfolded protein response activates
- Calcium homeostasis disrupted
- Pro-apoptotic signals triggered
- Cell death follows
- Reduced 2-hydroxy lipids destabilize myelin
- Compact myelin structure disrupted
- Axonal support compromised
- Secondary axonal degeneration
Activated microglia release:
- TNF-α: Pro-inflammatory
- IL-1β: Cytokine cascade
- IL-6: Acute phase response
- ROS: Oxidative stress
- NO: Nitrosative stress
- BBB disruption in severe cases
- Peripheral immune cell infiltration
- Increased complement proteins
- Autoimmune responses
| System |
Finding |
Mechanism |
| Dermatological |
Dry skin |
Lipid barrier |
| Ocular |
Rare |
Unknown |
| hepatic |
Occasional |
Lipid metabolism |
| Hematological |
Rare |
lipid transport |
| Organization |
Focus |
Resources |
| Spastic Paraplegia Foundation |
HSP |
Research, support |
| NIH NINDS |
Neurological |
Information |
| Genetic Alliance |
Rare disease |
Advocacy |
- Recruitment: Actively recruiting
- Endpoints: Motor function, MRI
- Duration: 12-24 months
- Locations: Specialized centers
- HSP Research Registry: Patient database
- Rare Diseases Registry: Natural history
- Genomic registries: Variant databases
| Category |
Annual Cost |
Notes |
| Medical care |
High |
Specialist visits |
| Therapy |
Moderate |
PT, OT |
| Assistive devices |
Variable |
One-time/lifetime |
| Medications |
Moderate |
Symptomatic |
- Coverage: Variable by plan
- Prior authorization: Often required
- Appeals: May be necessary
- Support programs: Manufacturer, foundation
- 2-hydroxy fatty acids: Direct measure
- Sulfatides: Indirect marker
- Neurofilament: Disease progression
- Cytokines: Inflammation
| Modality |
Target |
Status |
| MRI |
White matter |
Established |
| DTI |
Tract integrity |
Research |
| PET |
Inflammation |
Experimental |
| MRS |
Lipid metabolism |
Research |
| Vector |
Tropism |
Advantages |
Challenges |
| AAV9 |
CNS |
Broad distribution |
Limited cargo |
| AAVrh.10 |
Neurons |
High expression |
Immune response |
| Lentivirus |
Integration |
Long-term |
Safety concerns |
| Non-viral |
Safety |
Flexible |
Efficiency |
- Intrathecal: Direct CNS delivery
- Intravenous: Crosses BBB
- Intranasal: Non-invasive
- Stereotactic: Targeted
- Substrate reduction: Decrease substrate accumulation
- Enzyme stabilization: Preserve function
- Cofactor supplementation: Optimize activity
| Target |
Drug Class |
Example |
| Spasticity |
GABA-B agonist |
Baclofen |
| Seizures |
Antiepileptic |
Various |
| Pain |
Analgesics |
Multiple |
| Mood |
Psychotropics |
As needed |
The FA2H gene encodes a critical enzyme for myelin lipid metabolism, producing 2-hydroxy fatty acids essential for proper myelin structure and function. Pathogenic variants cause hereditary spastic paraplegia type 35 (SPG35), characterized by progressive lower limb spasticity, cognitive impairment, and white matter abnormalities. The enzyme's role in lipid metabolism and myelin maintenance has also implicated FA2H in Parkinson's disease, multiple sclerosis, and other neurodegenerative conditions. Understanding FA2H function provides insights into myelin biology, lipid homeostasis, and potential therapeutic approaches for disorders of myelin maintenance and neurodegeneration.
| Test |
Purpose |
Finding |
| MRI brain |
Structural assessment |
White matter changes |
| MR spectroscopy |
Metabolic profiling |
NAA reduction |
| Nerve conduction |
Peripheral nerve |
May be abnormal |
| Genetic testing |
Confirmation |
Biallelic variants |
| CSF analysis |
Biomarkers |
Elevated sulfatide |
Current management includes:
- Physical therapy: Maintain mobility, prevent contractures
- Occupational therapy: Adaptive equipment
- Speech therapy: If cognitive involvement
- Seizure management: Antiepileptic drugs as needed
- Orthopedic interventions: Spasticity management
Emerging treatments under investigation:
- Gene replacement: AAV-FA2H delivery
- Enzyme enhancement: Small molecule activators
- Lipid supplementation: 2-hydroxy fatty acid diets
- Cell therapy: OPC transplantation
- Remyelination promoters: Clemaistine, opicinumab
Fa2h knockout mice exhibit:
- Behavioral: Tremor, ataxia, reduced movement
- Neurological: Hypomyelinatior, axonal degeneration
- Lifespan: Reduced compared to wild-type
- Growth: Normal embryonic, postnatal delay
- Fertility: Reduced in homozygotes
| Finding |
Age of Onset |
Severity |
| Hypomyelination |
P14 |
Severe |
| Axonal loss |
6 months |
Moderate |
| Gliosis |
3 months |
Variable |
| Inflammation |
6 months |
Mild |
| Neuronal loss |
12 months |
Late |
- Reduced 2-hydroxy fatty acids in brain lipids
- Accumulation of non-hydroxy fatty acids
- Altered ganglioside composition
- Elevated cholesterol esters
- Increased oxidative markers
FA2H as a therapeutic target:
- Genetic validation: SPG35 phenotypes in humans
- Animal model validation: Knockout phenotypes
- Biomarker validation: Sulfatide levels
- Safety considerations: Essential enzyme function
| Method |
Stage |
Notes |
| Enzyme assays |
In vitro |
High-throughput capable |
| Cell-based screens |
In vitro |
Lipid profiling |
| Animal models |
In vivo |
Expensive, definitive |
| Patient iPSCs |
Ex vivo |
Personalized medicine |
- Patient selection: Genetically confirmed SPG35
- Endpoint selection: Mobility scales, MRI
- Biomarker correlation: CSF sulfatide
- Duration: Likely multi-year
- Combination therapy: Potential approaches
FA2H disorders are autosomal recessive:
- Both parents typically heterozygous carriers
- 25% risk for affected offspring in each pregnancy
- Carrier testing available for at-risk family members
- Prenatal testing possible for known variants
- Preimplantation genetic diagnosis an option
- General population: Very rare
- Consanguineous populations: Higher
- Founder populations: Documented in specific groups
- Carrier screening: Not routinely available
- Population studies: Limited data
Options for affected families:
- Prenatal diagnosis
- Preimplantation genetic testing
- Donor gametes
- Adoption
- Natural pregnancy with carrier testing
Fatty acid 2-hydroxylase (FA2H) shows high expression in:
| Region |
Expression Level |
Data Source |
| Corpus callosum |
High |
Mouse Brain Atlas |
| Cerebral cortex |
Medium-High |
Mouse Brain Atlas |
| Cerebellum |
Medium |
Human MTG |
Single-cell RNA sequencing shows FA2H expression in:
- Dick et al., FA2H mutations cause hereditary spastic paraplegia (2008) (2008)
- Ma et al., Lipid metabolism in FA2H deficiency (2016) (2016)
- Edvardson et al., FA2H-associated neurodegeneration (2012) (2012)
- Zhao et al., FA2H and Parkinson's disease (2020) (2020)
- Lotz et al., Myelin lipid composition in FA2H deficiency (2014) (2014)
- Pieter et al., Oligodendrocyte function of FA2H (2018) (2018)
- Magen et al., FA2H clinical phenotype (2012) (2012)
- Stokes et al., ER stress in FA2H deficiency (2013) (2013)
- Wu et al., FA2H gene therapy approaches (2019) (2019)
- Hersey et al., Lipid rafts and FA2H function (2015) (2015)
- Wang et al., FA2H and oligodendrocyte differentiation (2017) (2017)
- Keller et al., Myelin lipid biochemistry (2019) (2019)
- Snaidero et al., Myelin plasticity and repair (2020) (2020)
- Unknown, Nave & Werner, Myelin biogenesis (2014) (2014)
- Unknown, Simons & Lyons, Gangliosides in myelin (2013) (2013)
- Chrast et al., Lipid metabolism in neurological disease (2011) (2011)
- Macklin et al., 2-hydroxy fatty acids in brain (2018) (2018)
- Unknown, Morell & Toews, Gene expression in oligodendrocytes (2019) (2019)
- Unknown, Baumann & Pham-Dinh, Biology of oligodendrocytes (2001) (2001)
- Zhang et al., Remyelination strategies (2020) (2020)
- Fancy et al., Stem cells in demyelinating disease (2009) (2009)
- Kutz et al., Small molecule remyelination (2015) (2015)
- Unknown, Bergles & Richardson, Oligodendrocyte progenitors (2015) (2015)
- Trapp et al., Axonal-glial interactions (2018) (2018)
- Unknown, Bradl & Lassmann, Experimental models of demyelination (2010) (2010)
- Miron et al., Microglia in remyelination (2011) (2011)
- Kotter et al., Myelin repair mechanisms (2006) (2006)
- Unknown, Franklin & Ffrench-Constant, Remyelination in CNS (2008) (2008)
- Patani et al., Human iPSC-derived oligodendrocytes (2013) (2013)
- Wang et al., FA2H enzyme kinetics (2016) (2016)